Minimally Invasive Delivery of a Novel Anti-Inflammatory SoloMER® Biologic using Microarray Patches

Anjali Pandya – PostDoc, Queen's University Belfast; Caroline Barelle – Chief Executive Officer, Elasmogen; Obinna Ubah – Principal Scientist, Elasmogen; Ryan Donnelly – Professor, Queen's University Belfast

Introduction:

Monoclonal antibodies have transformed modern medicine, but their large size can restrict tissue penetration, often requiring parenteral dosing and raising formulation and patient acceptability challenges.  Variable new antigen receptors (VNARs) are next-generation biologics, combining small size, high stability and access to otherwise hidden epitopes (1). Microarray patches (MAPs) (Fig.1. A, B) enable minimally invasive, needle-free delivery to overcome these challenges (2). Dissolving and hydrogel-forming MAPs were investigated for the delivery of ELN22-108 across neonatal porcine skin ex vivo.